Comparing newborn outcomes after prenatal exposure to individual antidepressants: A retrospective cohort study

Pharmacotherapy. 2021 Nov;41(11):907-914. doi: 10.1002/phar.2628. Epub 2021 Oct 26.

Abstract

Objective: To compare associations between individual antidepressants and newborn outcomes.

Design: Retrospective cohort study.

Setting: Deliveries in a large, US medical system.

Population: Women who received at least one antidepressant prescription 3 months prior to conception through delivery.

Methods: Eligible women had maternal characteristics and newborn outcomes extracted from medical record data. Exposure was defined by the timing of the prescription during pregnancy.

Main outcome measures: Newborn outcomes (any adaptation syndrome, neonatal intensive care unit (NICU) admission) were analyzed for each antidepressant and compared using standard statistics and multivariable regression compared to exposure to bupropion. Odds of outcomes based on timing of exposure were also explored.

Results: A total of 3,694 women were analyzed. Rates of any adaptation syndrome (p < 0.001), NICU admission (p < 0.001), and transient tachypnea of newborn (TTN) (p = 0.006) were significantly different between drugs. Infants exposed to duloxetine had the highest rates of NICU admissions (39.6%) and adaptation syndromes (15.1%). Venlafaxine-exposed infants had the highest rates of TTN (18.2%). Controlling for maternal age, race, insurance, and gestational age at delivery, early pregnancy antidepressant exposure was associated with adaptation syndrome and NICU admission for both duloxetine (adjusted odds ratio (aOR) 2.31 [95% Confidence Interval (CI) 1.11-4.80] and aOR 2.47 [95% CI 1.40-4.34], respectively) and escitalopram (aOR 1.72 [95% CI 1.09-2.70] and aOR 1.64 [95% CI 1.21-2.22], respectively). Exposure in the third trimester was associated with any adaptation syndrome for citalopram, duloxetine, escitalopram, fluoxetine, sertraline, and venlafaxine and NICU admission for bupropion, citalopram, duloxetine, escitalopram, and fluoxetine.

Conclusion: Duloxetine and escitalopram appear to have the strongest associations with any adaptation syndrome and NICU admission whereas bupropion and sertraline tended to have among the lowest risks of these outcomes. These results can help providers and patients discuss choice of individual antidepressant drugs during pregnancy.

Keywords: abstinence syndrome; antidepressants; exposure; newborn outcomes; pregnancy.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antidepressive Agents* / adverse effects
  • Bupropion / adverse effects
  • Citalopram / adverse effects
  • Duloxetine Hydrochloride / adverse effects
  • Escitalopram / adverse effects
  • Female
  • Fluoxetine / adverse effects
  • Humans
  • Infant, Newborn
  • Pregnancy
  • Prenatal Exposure Delayed Effects* / epidemiology
  • Retrospective Studies
  • Sertraline / adverse effects
  • Treatment Outcome
  • Venlafaxine Hydrochloride / adverse effects

Substances

  • Antidepressive Agents
  • Fluoxetine
  • Bupropion
  • Citalopram
  • Escitalopram
  • Venlafaxine Hydrochloride
  • Duloxetine Hydrochloride
  • Sertraline